The recent findings of the National Lung Screening Trial showed 24.2% of individuals at high risk for lung cancer having one or more indeterminate nodules detected by low-dose computed tomography-based screening, 96.4% of which were eventually confirmed as false positives. These positive scans necessitate additional diagnostic procedures to establish a definitive diagnosis that adds cost and risk to the paradigm. A plasma test able to assign benign versus malignant pathology in high-risk patients would be an invaluable tool to complement low-dose computed tomography-based screening and promote its rapid implementation. Methods: We evaluated 17 biomarkers, previously shown to have value in detecting lung cancer, against a discovery cohort, comprising benign (n = 67) cases and lung cancer (n = 69) cases. A Random Forest method based analysis was used to identify the optimal biomarker panel for assigning disease status, which was then validated against a cohort from the Mayo Clinic, comprising patients with benign (n = 61) or malignant (n = 20) indeterminate lung nodules. Results: Our discovery efforts produced a seven-analyte plasma biomarker panel consisting of interleukin 6 (IL-6), IL-10, IL-1ra, sIL-2Rα, stromal cell-derived factor-1α+β, tumor necrosis factor α, and macrophage inflammatory protein 1 α. The sensitivity and specificity of our panel in our validation cohort is 95.0% and 23.3%, respectively. The validated negative predictive value of our panel was 93.8%.
T he American Cancer Society estimates more than 226,160 new cases of lung cancer and approximately 160,340 lung cancer deaths in 2012, making it the most common cause of malignancy-related mortality in the United States. 1 Nonsmall-cell lung cancer (NSCLC) carries a dismal prognosis with a 5-year survival rate estimated to be less than 16%. Poor survival is partly because of the fact that 85% of lung cancer cases are diagnosed after metastatic disease progression, when curative treatment options are no longer available. Diagnosis of NSCLC before the development of extensive locoregional or distant metastases promises to improve 5-year survival rates by 60% to 80%. 2 Efforts have been made since the early 1970s to identify screening methods for early detection of NSCLC. Unfortunately, neither chest radiography nor sputum cytology proved to be effective. [3] [4] [5] [6] Single-arm prospective uncontrolled studies on low-dose computed tomography (LDCT) of the chest screening yielded conflicting results. 1, 7 Recently, the National Lung Screening Trial (NLST) demonstrated a 20% relative reduction in lung cancer mortality with LDCT screening of high-risk patients compared with annual chest radiograph with a median follow-up of 6.5 years. 8 High risk in patients was defined by this study to be individuals aged 55 to 74 years, having a smoking history of more than 30 pack-years, and having quit less than 15 years before randomization.
The approach to indeterminate screen-detected lung nodules in high-risk populations can represent significant challenges for the clinician. Data from the NLST showed that 24.2% of screening LDCT scans were positive, with 96.4% of these nodules determined as false positives. 8 An individual has an incidence of 33% of a false positive LDCT scan after two rounds of annual screening, and 7% of these individuals go through unnecessary invasive procedures to prove benign disease. 9 Avoidance of these unnecessary invasive procedures would benefit patient safety. The analysis for the In addition, it is estimated to cost $240,000 per one life saved by LDCT screening. 9 Decreasing the cost of LDCT screening by decreasing the need for subsequent invasive thoracic procedures or continued radiographic follow-up is paramount.
The potential of individual serum biomarkers to predict malignancy in indeterminate lung nodules has been researched and met with limited success. Published data on individual serum biomarkers, most notably cytokeratin 19 fragment 21.1, carcinoembryonic antigen, and tissue plasminogen activator in NSCLC show limited sensitivity and specificity, particularly in early-stage disease. 10, 11 The objective of our study is to develop and validate a plasma biomarker panel with test characteristics compatible with its use as a companion test in high-risk patients with screening LDCT-detected indeterminate lung nodules.
PATIENTS AND METHODS

Patient Cohorts
Between 2004 and 2010, we enrolled 136 patients at Rush University Medical Center (RUMC) and divided them into the following cohorts: (a) pathologically diagnosed lymph-node negative lung cancer (n = 69) and (b) benign disease (n = 67). All stage classifications were according to the 7th edition criteria 12, 13 and were pathologically confirmed. Patients with benign resected disease (n = 35) were diagnosed with granulomatous inflammation (n = 21), nonspecific inflammatory changes (n = 9), and lung infections (n = 5). The remaining patients in our benign cohort were part of an internal screening program with LDCT-determined benign disease (n = 32). Inclusion criteria for individuals enrolled in our screening program were ages of 50 years or more, or smoking history of more than 20 pack-years. All participants were followed with annual LDCT and remained cancer-free for a minimum 2-year follow-up. Demographic information for these patient groups are contained in Table 1 . Our validation population (n = 81) consisted of the following cohorts received from our collaboration with the Mayo Clinic: (a) pathologically diagnosed lymph-node negative lung cancer (n = 20) and (b) benign disease (n = 61). Demographic information is contained in Table 2 . All patient data was acquired with written informed consent and in absolute compliance with the Institutional Review Board at either Rush University Medical Center or the Mayo Clinic.
Measurement of Plasma Biomarker Concentrations
Plasma was prepared using standard phlebotomy protocols from peripheral blood collected in yellow-top tubes either immediately before an anatomical resection, or in conjunction with a lung cancer screening trial. No specimen was subjected to more than two freeze and thaw cycles. [14] [15] [16] [17] Seventeen candidate biomarkers were used for discovery based on previously shown success in differentiating NSCLC from benign disease. 15 Assays for CA-125, cytokeratin 19 fragment 21-1, osteopontin, stromal cell-derived factor -1(α+β) (Millipore, Billerica, MA) were measured as a four-plex assay kit; interleukin-1 receptor antagonist (IL-1ra), sIL-2R α , IL-6, IL-10, Eotaxin, monocyte chemotactic protein 1, macrophage inflammatory protein-1α, tumor necrosis factor alpha (TNF-α) (Millipore) as an eight-plex assay kit; and sE-Selectin, sICAM-1 (Millipore) as a two-plex assay kit. The remaining plasma biomarkers (Millipore) were run individually and consisted of soluble epidermal growth factor receptor (sEGFR) matrix metalloproteinase 2, and C-reactive protein. All biomarker concentrations were calculated with a five-parametric curve fit, using xPONENT v4.0.3 (Luminex Corp., Austin, TX) in a blinded fashion, using data collected on a Luminex FlexMAP 3D system. Table 3 lists the 17 biomarkers evaluated in this study.
Statistical Methods
Methods for candidate biomarker testing were consistent with those previously reported by our group.
14-17 Descriptive statistics were obtained along with receiver operator characteristics parameters (including area under the curve [AUC]) to assess the performance of the 17 individual candidate biomarkers, using SPSS 18.0 for Windows (SPSS Inc., Chicago, IL). The Mann-Whitney rank sum test was used to evaluate differences in biomarker concentrations. A threshold for significance as a biomarker was set to an AUC of greater than 0.60 or a Mann-Whitney rank sum (2-sided) p value less than 0.05. The optimal multivariate panel was selected using variable selection based on importance scores from the Random Forests method as we previously described. 14 Sensitivity, specificity, and negative predictive value were used to evaluate performance of our biomarker panel. The biomarker panel selected, based on data from the discovery cohort, was then used to make predictions of disease in our validation cohort (Mayo Clinic, Rochester, MN) in a blinded fashion (where the statistician is kept completely blinded of the true disease status data in the validation cohort).
RESULTS
The median age of the patients with benign disease in our screening cohort was 61 years whereas our benign resected cohort's median age was 65 years (range, 20-82). In comparison, the median age of patients in our lung cancer cohort was 67 years (range, 48-83). The median pack-year smoking history of patients with benign disease in our screening cohort was 36 pack-years (range, 6-126) whereas our benign resected cohort's median smoking history was 1 pack-year (range, 0-60). The median pack-year smoking history of our lung cancer cohort was 35 pack-years (range, 0-120). Univariate analysis of the RUMC discovery cohort data, using receiver operator characteristics curve parameters, revealed nine biomarkers of the 17 tested with an AUC more than 0.60, and eight biomarkers to be significantly different in indeterminate nodules between the lung cancer and the benign disease groups, as shown in Table 3 . Four biomarkers showed strong significance (p < 0.01) for identifying lung cancer in indeterminate nodules and include IL-1ra, IL-10, CA-125 and sE-Selectin. All four biomarkers were shown to have significantly elevated levels in patients with lung cancer.
Multivariate analysis of the data from only the RUMC discovery cohort patients, using variable selection based on Random Forests method, resulted in a seven-analyte panel consisting of IL-6, IL-10, IL-1ra, sIL-2R α , SDF-1α+β, TNF-α, and MIP-1α. This Random Forest-generated panel differentiated patients with NSCLC from patients with benign disease with a crossvalidated accuracy of 76.5%. This panel provided 35 cases of true negatives, 69 cases of true positives, 32 cases of false positives, and zero cases of false negatives for a calculated sensitivity of 100%, specificity of 52.2%, and a negative predictive value of 100%. The AUC was calculated to be 0.910 (Fig. 1) .
The Random Forest-generated seven-analyte panel developed on the Rush Cohort was then used to predict the disease status in the validation cohort from the Mayo Clinic in a blinded fashion. The panel differentiated patients with lung cancer (n = 20) from patients with benign disease (n = 61) with an accuracy of 42.0%. This panel provided 15 cases of true negatives, 19 cases of true positives, 46 cases of false positives, and one case of false negative for a calculated sensitivity of 95.0%, specificity of 24.6%, and a negative predictive value of 93.8%. The AUC was calculated to be 0.676 (see Fig. 2 ).
DISCUSSION
The primary goal of LDCT screening programs is to detect asymptomatic disease in patients at high risk for lung cancer, therefore, increasing eligibility for surgical intervention with curative intent and greatly improving prognosis. Currently, an estimated 7 million individuals in the United States qualify for lung cancer screening, based on the NLST inclusion criteria. 8 If CT-based screening protocols were implemented today, the health care system would be burdened by the 1.6 to 3.5 million indeterminate nodules identified by LDCT screening. 18, 19 Under current guidelines, positive screening LDCT scans are stratified by nodule size to determine lung cancer risk and diagnostic recommendations. It is recommended that nodules less than 4 mm, 4 to 6 mm, and 6 to 8 mm are followed by LDCT screening at annual, 6-month, and 3-month intervals, respectively. 20 Nodules greater than 8 mm should be investigated further with positron emission tomography scan and/or biopsy. A significant number of patients will undergo invasive procedures to further characterize these indeterminate nodules, and according to the NLST data, 96% of those nodules will prove to be benign.
As a result of the NLST trial, the International Association for the Study of Lung Cancer (IASLC) recently published a position statement with regard to LDCT screening. 21 The IASLC appointed a Strategic CT Screening Advisory Committee (SSAC) to deliver guidelines and recommendations in six key areas of LDCT screening. One specific focus of the SSAC was to develop guidelines for the clinical workup of indeterminate nodules resulting from LDCT screening. Within these guidelines, the IASLC-SSAC recognized the need for further investigation of biomarkers as a complement to address the high number of false-positive cases with LDCT screening. 21 LDCT screening, with successful discovery of biomarkers capable of increasing its efficacy, can evolve into a universally available tool for clinicians.
Our discovery effort for the development of our plasma biomarker panel refined previous efforts made by our group to develop a serum biomarker panel capable of predicting NSCLC versus benign disease. [14] [15] [16] [17] We reevaluated significant biomarkers, which previously showed value in serum for predicting NSCLC versus benign disease, and used them to determine value in plasma for predicting NSCLC versus benign disease in patients with indeterminate nodules. Large national cancer repositories have focused efforts to store plasma for the development and validation of biomarker panels. 22 As a result, the use of plasma as the matrix for discovery and validation is crucial for future validations. Our plasma biomarker panel consisted of IL-6, IL-10, IL-1ra, sIL-2R α , SDF-1α+β, TNF-α and MIP-1α. Our plasma panel biomarker shares three analytes (IL-1R α , TNF-α, MIP-1α) with our previous serum biomarker panel, which was successful for predicting NSCLC versus benign disease. 15 Our plasma biomarker panel was able to predict lung cancer versus benign disease in our discovery cohort with an accuracy of 76.5%. Our panel accuracy was affected by a larger than expected number of false-positive cases (n = 32). The clinical value of our plasma biomarker panel is its ability to effectively rule out lung cancer in patients with indeterminate nodules when the panel predicts benign disease (negative predictive value). The negative predictive value of our plasma biomarker test was 100% in our discovery cohort, with no false-negative cases observed. The observed high sensitivity (100%) and high negative predictive value (100%) of our plasma biomarker panel in our discovery cohort was suspect for apparent overfitting of the data, despite attempts to avoid this bias with Random Forest multivariate analysis. Validation studies, however, demonstrated that this was not the case.
Blinded validation of our plasma biomarker panel was performed against an external cohort of patients in collaboration with investigators from the Mayo Clinic. The difficulty in our ability to accurately predict lung cancer versus benign disease (41.3%) in our validation cohort was again the result of an increased number of false-positive cases (n = 46) and not as a result of false-negative cases. The negative predictive value of our test in our validation cohort remained high at 93.8%, with only one false-negative case. Despite an increased number of false-positive cases in our validation cohort, the clinical value of our plasma biomarker panel is unaffected. The panel's ability to effectively rule out lung cancer in patients with indeterminate nodules, when the panel predicts benign disease, remains unchanged by false positives. Our plasma biomarker panel would have accurately captured 15.4% of patients, who would otherwise have undergone unnecessary surgical biopsy, and moved them to a more conservative treatment arm of serial LDCT screening.
Despite a sensitivity of 100% and 95% in our discovery and validation cohort, respectively, the specificity remained low (52.2% and 23.3%, respectively) in the two cohorts. Although our biomarker panel is efficient at finding disease in a patient with lung cancer, our panel is poor at singling out patients with benign disease. This is a result of 32 and 46 false-positive cases in our discovery and validation cohort, respectively. Despite the low specificity of our biomarker panel, our panel could lead to significant reduction in morbidity, mortality, and health care costs. In fact, the current cost of materials and labor per patient for the Luminex-based plasma test presented in this study is $48, making this cost-effective and capable of being performed at most hospitals and medical centers across the United States. Efforts are currently ongoing in our laboratory to identify new biomarkers, using proteomic and immunoproteomic methods to improve the overall accuracy of our plasma test. In addition, efforts will be made to expand our cohorts to include a larger percentage of patients with squamous cell carcinoma, as this subgroup provides unique tumor antigens that enhance the overall value to our plasma biomarker panel.
Few other blood tests seem ready for clinical use for assigning clinical significance to indeterminate nodules. Two such panels include the EarlyCDT-Lung test manufactured by Oncimmune, Limited (Nottingham, Great Britain) 23, 24 and a multianalyte serum biomarker panel by Bigbee et al. 25 The EarlyCDT-Lung test consists of autoantibodies against p53, NY-ESO-1 (cancer-testis antigen), cancer-associated antigen, GBU4-5, annexin I, and SRY (sex determining region Y) -box 2 (SOX2), and has been extensively tested and validated against earlystage lung cancer patients and control patients. 23, 24 However, clinical validation of this test provides an average sensitivity of 39% and specificity of approximately 90%. More recently, Bigbee et al. 25 reported the validation of an eleven-analyte serum biomarker panel for predicting the level of cancer risk in high-risk individuals with indeterminate lung nodules. 25 This serum biomarker panel consisted of prolactin, transthyretin, thrombospondin-1, sE-selectin, C-C motif chemokine 5 (CCL5; RANTES), macrophage migration inhibitory factor (MIF), plasminogen activator inhibitor, tyrosine-protein kinase, erbb-2, cytokeratin fragment 19 (CYFRA 21-1), and serum amyloid A (SAA). The serum biomarker panel achieved a sensitivity and specificity of 73.3% and 93.3%, respectively in their validation cohort. 25 The positive predictive value of the published serum panel was an impressive 92.3%, however, this feature will have a modest clinical impact because of the fact that confirming cancer in these patients does not change the treatment plan as all, regardless, will receive subsequent invasive procedures. Alternatively, the negative predictive value of the Bigbee et al. 25 serum biomarker panel in validation studies was very good at 77.8% and will help clinical management of a screening population. We intend to explore some of the biomarker targets identified by this study as a means to improve the positive predictive value of our panel.
In conclusion, we have developed a test with a negative predictive value, which will allow clinicians to confidently rule out malignancy in indeterminate pulmonary nodules found during LDCT screening. In addition to the cost advantage to the health care system, this assay may offer rapid result capability (< 24 hours) and will reduce patient anxiety inherent in current diagnostic methods, which may take as long as 6 months to complete. To continue in our objective to bring a highly functioning plasma biomarker panel to clinical use, our next step includes a large-scale validation with cooperation of the Early Detection Research Network and the American College of Radiology Imaging Network-National Lung Screening Trial. Furthermore, a large-scale proteomic discovery approach will soon be initiated, which will allow us to improve our positive predictive value and generate a more optimal version of our test for clinical implementation. Successful large-scale validation will allow our group to employ our plasma biomarker panel in large prospective clinical trials with the ultimate goal of producing a highly efficient tool for clinicians to use in their practice.
